Literature DB >> 20955397

Different clinical severity of first episodes and recurrences of thrombotic thrombocytopenic purpura.

Luca A Lotta1, Mariagabriella Mariani, Dario Consonni, Ilaria Mancini, Roberta Palla, Alberto Maino, Dragica Vucelic, Michele Pizzuti, Pier M Mannucci, Flora Peyvandi.   

Abstract

The clinical course of thrombotic thrombocytopenic purpura (TTP) is characterized by recurrent disease episodes in up to 50% of cases. The clinical presentation and severity of different TTP episodes have not been systematically compared. Laboratory and clinical information from 51 patients with recurrent disease, derived from 136 patients with TTP included in the Milan TTP registry (URL: http://www.ttpdatabase.org), were used to compare mortality, symptoms and disease-related laboratory measurements in different disease episodes. The prevalence of severe neurological symptoms (coma, seizures, and focal neurological defects) was significantly lower in recurrences than in the first episode. Platelet counts and haemoglobin levels at presentation were higher in recurrences than in the first disease episode, and lactate dehydrogenase levels were lower. Also, mortality tended to be lower in the second and third disease episodes than in the first. Recurrences of TTP are generally milder than first episodes. These differences in severity should be taken into account in clinical research on TTP and in patient management.
© 2010 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20955397     DOI: 10.1111/j.1365-2141.2010.08385.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Case report: use of thienopyridines in a patient with acquired idiopathic thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Ilaria Mancini; Giacomo Tuana; Khaled M Musallam; Flora Peyvandi
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

2.  Lombardy diagnostic and therapeutic network of thrombotic microangiopathy.

Authors:  I Mancini; P Agosti; M Boscarino; B Ferrari; A Artoni; R Palla; M Spreafico; G Crovetti; E Volpato; S Rossini; C Novelli; S Gattillo; L Barcella; M Salmoiraghi; A Falanga; F Peyvandi
Journal:  Orphanet J Rare Dis       Date:  2022-06-23       Impact factor: 4.303

3.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

4.  Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.

Authors:  Ygal Benhamou; Cyrielle Assié; Pierre-Yves Boelle; Marc Buffet; Rana Grillberger; Sandrine Malot; Alain Wynckel; Claire Presne; Gabriel Choukroun; Pascale Poullin; François Provôt; Didier Gruson; Mohamed Hamidou; Dominique Bordessoule; Jacques Pourrat; Jean-Paul Mira; Véronique Le Guern; Claire Pouteil-Noble; Cédric Daubin; Philippe Vanhille; Eric Rondeau; Jean-Bernard Palcoux; Christiane Mousson; Cécile Vigneau; Guy Bonmarchand; Bertrand Guidet; Lionel Galicier; Elie Azoulay; Hanspeter Rottensteiner; Agnès Veyradier; Paul Coppo
Journal:  Haematologica       Date:  2012-05-11       Impact factor: 9.941

Review 5.  Postoperative thrombotic thrombocytopenic purpura.

Authors:  Ahmet Emre Eskazan; Deram Buyuktas; Teoman Soysal
Journal:  Surg Today       Date:  2013-12-29       Impact factor: 2.549

6.  Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura.

Authors:  Luca A Lotta; Haifeng M Wu; Ian J Mackie; Marina Noris; Agnes Veyradier; Marie A Scully; Giuseppe Remuzzi; Paul Coppo; Ri Liesner; Roberta Donadelli; Chantal Loirat; Richard A Gibbs; April Horne; Shangbin Yang; Isabella Garagiola; Khaled M Musallam; Flora Peyvandi
Journal:  Blood       Date:  2012-04-23       Impact factor: 22.113

Review 7.  Successful preventive treatment with cyclosporine in a patient with relapsed/refractory immune-mediated thrombotic thrombocytopenic purpura: a case report and review of the literature.

Authors:  Kaori Uchino; Kazuya Sakai; Saki Shinohara; Akifumi Matsuhisa; Yusuke Iida; Yuta Nakano; Saori Matsumura; Jo Kanasugi; Soichi Takasugi; Ayano Nakamura; Tomohiro Horio; Satsuki Murakami; Shohei Mizuno; Hidesuke Yamamoto; Ichiro Hanamura; Masanori Matsumoto; Akiyoshi Takami
Journal:  Int J Hematol       Date:  2022-03-10       Impact factor: 2.319

Review 8.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615

9.  Thrombotic Thrombocytopenic Purpura Triggered by Acute Myeloid Leukemia: A Case Report.

Authors:  Ijele Adimora; Cristhiam M Rojas Hernandez
Journal:  Am J Case Rep       Date:  2022-08-30

10.  Neurological manifestations in thrombotic microangiopathy: Imaging features, risk factors and clinical course.

Authors:  José Thiago de Souza de Castro; Simone Appenzeller; Marina Pereira Colella; Gabriela Yamaguti-Hayakawa; Erich Vinícius De Paula; Joyce Annichinno-Bizzachi; Fernando Cendes; Reis Fabiano; Fernanda Andrade Orsi
Journal:  PLoS One       Date:  2022-09-21       Impact factor: 3.752

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.